Skip to main content

Nationwide survey of anti-tuberculosis drug resistance in Mongolia

Buy Article:

$34.78 + tax (Refund Policy)

BACKGROUND: Drug-resistant tuberculosis (TB) has emerged as an obstacle to effective TB control.

SETTING: The eight district and 21 province TB dispensaries and the two TB hospitals comprising the diagnostic centers for TB in Mongolia.

METHODS: To investigate drug resistance levels among new and retreated TB cases. Specifically, we determined the prevalence of resistance to rifampin, streptomycin, isoniazid and ethambutol among TB patients with and without prior anti-tuberculosis treatment.

RESULTS: A total of 850 patients (74.1% of eligible and 78.0% of patients with a specimen) had Mycobacterium tuberculosis isolated and are the subject of this analysis. Of these, 200 had a history of prior treatment and 650 did not. Any multidrug resistance was found in 7.5% (95%CI 5.9–9.5), with respectively 27.5% (95%CI 21.8–34.1) and 1.4% (95%CI 0.7–1.6) of patients with and without prior history of treatment.

CONCLUSIONS: The most conspicuous finding in our survey was the relatively low prevalence of multidrug resistance among patients without a history of prior treatment, as compared to very high prevalence among previously treated patients. This suggests that retreatment is deficient and poses a threat to continued transmission, which has not yet manifested itself among new patients.

Keywords: DST; MDR-TB; TB

Document Type: Regular Paper

Affiliations: 1: National Center for Communicable Diseases, Ulaanbaatar, Mongolia 2: Research Institute for Tuberculosis, Tokyo, Japan 3: International Union Against Tuberculosis and Lung Disease, Paris, France; Institute of Social and Preventive Medicine, University of Zurich, Zurich, Switzerland

Publication date: 01 September 2011

More about this publication?
  • The International Journal of Tuberculosis and Lung Disease (IJTLD) is for clinical research and epidemiological studies on lung health, including articles on TB, TB-HIV and respiratory diseases such as COVID-19, asthma, COPD, child lung health and the hazards of tobacco and air pollution. Individuals and institutes can subscribe to the IJTLD online or in print – simply email us at [email protected] for details.

    The IJTLD is dedicated to understanding lung disease and to the dissemination of knowledge leading to better lung health. To allow us to share scientific research as rapidly as possible, the IJTLD is fast-tracking the publication of certain articles as preprints prior to their publication. Read fast-track articles.

  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • International Journal of Tuberculosis and Lung Disease
  • Public Health Action
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content